{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:54:14Z","timestamp":1760403254245,"version":"build-2065373602"},"reference-count":62,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Ixekizumab is a human monoclonal antibody targeting interleukin-17A, approved for the treatment of moderate-to-severe plaque psoriasis. Given its demonstrated efficacy and safety in clinical trials, this study aimed to evaluate the real-world drug survival of Ixekizumab and identify clinical predictors of treatment discontinuation. Materials and Methods: A retrospective, observational, hospital-based study was conducted in the Department of Dermatology at the Central University Hospital of Asturias (HUCA). Patients with moderate-to-severe plaque psoriasis who initiated treatment with Ixekizumab (Taltz\u00ae) between 8 June 2017 and 10 October 2024, were included. Demographic data, comorbidities, age at disease onset, family history, PASI score, and previous treatments were recorded. Drug survival was assessed using Kaplan\u2013Meier survival curves and the log-rank test. Predictors of discontinuation were analyzed using univariate and multivariate Cox proportional hazards models. Results: A total of 103 patients (55.3% women) were included. Drug survival rates were 85% at one year, 73% at two years, and 61% at four years, with a mean treatment duration of 52.5 months (95% CI: 46.01\u201358.99). Multivariate analysis showed that patients under the age of 65 had a significantly higher risk of treatment discontinuation (hazard ratio: 1.813; p &lt; 0.05). The most common reason for discontinuation was secondary treatment failure (45.16%). Ixekizumab demonstrated sustained drug survival in a real-world setting, with rates falling within the mid-to-upper range reported in the literature. Older age (&gt;65 years) was associated with greater treatment persistence, highlighting a potential influence of age on long-term therapeutic adherence.<\/jats:p>","DOI":"10.3390\/medicina61101827","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:13:27Z","timestamp":1760361207000},"page":"1827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Age Factor in Ixekizumab Survival: Older Patients Show Higher Long-Term Treatment Survival"],"prefix":"10.3390","volume":"61","author":[{"given":"In\u00e9s","family":"Noval-Mart\u00edn","sequence":"first","affiliation":[{"name":"GRIDER\u2014Grupo de Investigaci\u00f3n en Dermatolog\u00eda, Universidad de Oviedo, 33006 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-3522","authenticated-orcid":false,"given":"Jorge","family":"Santos-Juanes","sequence":"additional","affiliation":[{"name":"GRIDER\u2014Grupo de Investigaci\u00f3n en Dermatolog\u00eda, Universidad de Oviedo, 33006 Oviedo, Spain"},{"name":"Unidad de Gestion Cl\u00ednica de Dermatolog\u00eda, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"},{"name":"\u00c1rea de Dermatolog\u00eda, Departamento de Medicina, Universidad de Oviedo, 33006 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"\u00c1lvarez-Losada","sequence":"additional","affiliation":[{"name":"Reumatology Department, Hospital Universitario de Santiago, 27004 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Palacios-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Unidad de Gestion Cl\u00ednica de Dermatolog\u00eda, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-4379","authenticated-orcid":false,"given":"Ana","family":"Lozano-Blazquez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Garc\u00eda-Jimenez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-2863","authenticated-orcid":false,"given":"Cristina","family":"Galache Osuna","sequence":"additional","affiliation":[{"name":"GRIDER\u2014Grupo de Investigaci\u00f3n en Dermatolog\u00eda, Universidad de Oviedo, 33006 Oviedo, Spain"},{"name":"Unidad de Gestion Cl\u00ednica de Dermatolog\u00eda, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"},{"name":"\u00c1rea de Dermatolog\u00eda, Departamento de Medicina, Universidad de Oviedo, 33006 Oviedo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1644-1655","authenticated-orcid":false,"given":"Raquel Santos-Juanes","family":"Galache","sequence":"additional","affiliation":[{"name":"GRIDER\u2014Grupo de Investigaci\u00f3n en Dermatolog\u00eda, Universidad de Oviedo, 33006 Oviedo, Spain"},{"name":"Unidad de Gestion Cl\u00ednica de Dermatolog\u00eda, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,12]]},"reference":[{"key":"ref_1","first-page":"471","article-title":"Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol","volume":"7","author":"Dogra","year":"2016","journal-title":"Online J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Krueger","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2014Epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_4","first-page":"93","article-title":"Psoriasis vulgar moderada y severa: Opciones terap\u00e9uticas (tratamientos convencionales)","volume":"35","author":"Levrero","year":"2013","journal-title":"Arch. Med. Interna"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lee, H.J., and Kim, M. (2023). Challenges and future trends in the treatment of psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_8","first-page":"467","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ad.2016.09.021","article-title":"Clinical efficacy and safety of ixekizumab for treatment of psoriasis","volume":"108","author":"Azevedo","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (FDA) (2025, July 20). Taltz (Ixekizumab) Injection, for Subcutaneous Use: Initial U.S. Approval 2016 [Internet], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125521Orig1s000Approv.pdf."},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2016). Taltz: EPAR\u2013Product Information [Internet], EMA. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of Classic and Biological Systemic Drugs in Psoriasis: Results of the BIOBADADERM Registry and Critical Analysis","volume":"30","author":"Dauden","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Borr\u00e1s-Blasco, J., Valcuende-Rosique, A., and Cornejo-Uixeda, S. (2025). Letter to the editor regarding \u201cEfficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study\u201d. Int. Immunopharmacol., 164.","DOI":"10.1016\/j.intimp.2025.115370"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","article-title":"A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis","volume":"12","author":"Becher","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2023.2193288","article-title":"Real-life experience with ixekizumab in plaque psoriasis: A multi-center, retrospective, 3-year study","volume":"23","author":"Caldarola","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ntawuyamara, E., Deng, B., and Liang, Y. (2025). Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-99075-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_21","first-page":"4060","article-title":"Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: A single-center experience","volume":"27","author":"Burlando","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years","volume":"38","author":"Mastorino","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.12773","article-title":"Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis","volume":"29","author":"Saeki","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s13555-023-00969-1","article-title":"Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz customer support program","volume":"13","author":"Gottlieb","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s13555-022-00834-7","article-title":"Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry","volume":"12","author":"Lockshin","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Mu, Z., Zhao, Y., Zhang, J., and Cai, L. (2024). Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study. Int. Immunopharmacol., 143 Pt 2.","DOI":"10.1016\/j.intimp.2024.113474"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PTT.S456393","article-title":"Effectiveness and drug survival of ixekizumab and secukinumab in patients with moderate to severe plaque psoriasis: Real-world data from Bucharest, Romania","volume":"14","author":"Bucur","year":"2024","journal-title":"Psoriasis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40801-024-00439-w","article-title":"Six-month real-world study to assess the effectiveness of ixekizumab after switching from IL-23 inhibitors and other biologic therapies: The CorEvitas Psoriasis Registry","volume":"11","author":"Lebwohl","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pinter, A., Eyerich, K., Costanzo, A., Garrelts, A., Schuster, C., Mert, C., Lampropoulou, A., Fotiou, K., Maul, J.-T., and Papp, K.A. (2024). Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO). J. Dermatol. Treat., 35.","DOI":"10.1080\/09546634.2024.2350227"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s13555-023-01086-9","article-title":"Comparative effectiveness and durability of biologics in clinical practice: Month 12 outcomes from the international, observational psoriasis study of health outcomes (PSoHO)","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhdanava, M., Fitzgerald, T., Pilon, D., Teneralli, R.E., Shah, A., Diaz, L., Lefebvre, P., and Feldman, S.R. (2024). Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. J. Dermatol. Treat., 35.","DOI":"10.1080\/09546634.2024.2349658"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s13555-024-01134-y","article-title":"Effectiveness of ixekizumab in Chinese patients with moderate-severe plaque psoriasis with special area involvement: Subanalysis of a prospective, multicenter, observational real-world study","volume":"14","author":"Li","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s13555-024-01136-w","article-title":"Comparing achievement of National Psoriasis Foundation treatment targets among patients with plaque psoriasis treated with ixekizumab versus other biologics in clinical and real-world studies","volume":"14","author":"Armstrong","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1346-8138.17115","article-title":"Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study","volume":"51","author":"Valenti","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mucherino, S., Rafaniello, C., Serino, M., Zinzi, A., Trama, U., Capuano, A., Menditto, E., and Orlando, V. (2023). Drug utilization and measurement of medication adherence: A real-world study of psoriasis in Italy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122647"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Megna, M., Giunta, A., Carrera, C.G., Dapavo, P., Balato, A., Malagoli, P., Mazzoccoli, S., Parodi, A., and Sabatino, S. (2023). Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: Results from an Italian retrospective cohort study (the LOTIXE study). J. Dermatol. Treat., 34.","DOI":"10.1080\/09546634.2023.2246606"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, C., Torisu-Itakura, H., Hanada, T., Matsuo, T., Cai, Z., Osaga, S., and Aranishi, T. (2023). Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: A retrospective database study. J. Dermatol. Treat., 34.","DOI":"10.1080\/09546634.2023.2229465"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Reich, A., Reed, C., Schuster, C., Robert, C., Treuer, T., and Lubrano, E. (2023). Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: Literature review 2016\u20132021. J. Dermatol. Treat., 34.","DOI":"10.1080\/09546634.2022.2160196"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: A systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1007\/s12325-025-03258-9","article-title":"Real-world evidence for ixekizumab in the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Systematic literature review 2022\u20132023","volume":"42","author":"Puig","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/09546634.2020.1755009","article-title":"Moderate-to-severe plaque psoriasis patients treated with ixekizumab: Early real world outcomes and adverse events","volume":"33","author":"Gulliver","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.16214","article-title":"Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis","volume":"49","author":"Gooderham","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1346-8138.15146","article-title":"Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan","volume":"47","author":"Kishimoto","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors\u2014Brodalumab, ixekizumab, and secukinumab: Real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jaad.2019.01.034","article-title":"Real-world drug survival of ixekizumab for psoriasis","volume":"81","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/CCID.S387759","article-title":"Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study","volume":"15","author":"Li","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: Updated results from Slovenian National Registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lockshin, B., Cronin, A., Harrison, R.W., McLean, R.R., Anatale-Tardiff, L., Burge, R., Zhu, B., Malatestinic, W.N., Atiya, B., and Murage, M.J. (2021). Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry. Dermatol. Ther., 34.","DOI":"10.1111\/dth.14808"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/jdv.18827","article-title":"Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort","volume":"37","author":"Schots","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: A time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: A retrospective multi-country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1346-8138.16737","article-title":"Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study","volume":"50","author":"Yanase","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., Dapavo, P., and Dini, V. (2023). Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1341708"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","article-title":"Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA","volume":"13","author":"Fitzgerald","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Galache Osuna, C., G\u00f3mez-Vila, B., Aub\u00e1n Pariente, J., V\u00e1zquez Losada, B., G\u00f3mez de Castro, C., Requena L\u00f3pez, S., Vel\u00e1zquez, \u00c1.d.D., Garc\u00eda, L.P., Fern\u00e1ndez, L.O., and Diez, S.G. (2020). Ustekinumab drug survival in patients with psoriasis: A retrospective study of real clinical practice. Medicina, 56.","DOI":"10.3390\/medicina56110584"},{"key":"ref_56","first-page":"e258","article-title":"Comment on \u201cBaseline patients\u2019 characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments\u201d","volume":"60","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jaad.2019.04.072","article-title":"Comment on \u201cSecukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study\u201d","volume":"81","author":"Galache","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/ajd.14254","article-title":"Drug survival of biologics in psoriasis: An Australian multicentre retrospective study","volume":"65","author":"Ting","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s12325-024-02812-1","article-title":"Satisfaction with the injection experience of a new, citrate-free formulation of ixekizumab","volume":"41","author":"Chabra","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Malagoli, P., Dapavo, P., Pavia, G., Amoruso, F., Argenziano, G., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., and Dini, V. (2022). Real-life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study\u2014IL PSO (Italian landscape psoriasis). Dermatol. Ther., 35.","DOI":"10.1111\/dth.15608"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Osuna, C.G., Garc\u00eda, S.R., Mart\u00edn, J.C., Jim\u00e9nez, V.G., L\u00f3pez, F.V., and Santos-Juanes, J. (2021). Use of biological treatments in elderly patients with skin psoriasis in the real world. Life, 11.","DOI":"10.3390\/life11121348"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/1346-8138.17755","article-title":"Efficacy and safety of IL-17 and IL-23 inhibitors in elderly patients with plaque psoriasis: A real-world study","volume":"52","author":"Kartal","year":"2025","journal-title":"J. Dermatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:23:53Z","timestamp":1760369033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,12]]},"references-count":62,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101827"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101827","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,12]]}}}